Aripiprazole versus other atypical antipsychotics for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Khanna, Priya ^a   Komossa, Katja ^b   Rummel Kluge, Christine ^c   Hunger, Heike ^b   Schwarz, Sandra ^b   El Sayeh, Hany George ^d   Leucht, Stefan ^b  

^a East Midlands Workforce Deanery   (United Kingdom)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d HARROGATE DISTRICT HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOZAPINE; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AKATHISIA; BARNES AKATHISIA SCALE; BODY WEIGHT; BODY WEIGHT DISORDER; BODY WEIGHT GAIN; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; DIZZINESS; DRUG EFFECT; DRUG MANUFACTURE; DRUG SCREENING; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; HEADACHE; HUMAN; INCREASED APPETITE; INSOMNIA; MENTAL HEALTH; NAUSEA; OUTCOME ASSESSMENT; PARKINSONISM; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SIDE EFFECT; SIMPSON ANGUS SCA; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TREMOR; UPPER ABDOMINAL PAIN; XEROSTOMIA; META ANALYSIS;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA; THIAZOLES;

EID: 84875546504     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006569.pub4     Document Type: Review

References (386)

1. Chan HY, Lin WW, Lin SK, Hwang TJ, Su TP, Chiang SC, et al.Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: A randomized trial. Journal of Clinical Psychiatry 2007;68(1):29-36.
2. Hwang TJ, Chan HY, Lin WW, Lin SK, Hwu HG, Cheng MY, et al.Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. Journal of the European College of Neuropsychopharmacology 2005;14(Suppl 3):S497.
3. BMS. A multicenter, double-blind, randomized, comparative study of aripiprazole and olanzapine in the treatment of patients with acute schizophrenia. Clinical Study Report CN138003 2005.
4. Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, et al.Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Current Medical Research and Opinion 2011;27(1):115-22.
5. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Biological Psychiatry 2008;63(7 Suppl):289S.
6. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 63rd Annual Convention of the Society of Biological Psychiatry. 2008.
7. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, er al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Journal of Clinical Psychiatry 2009;70(4):572-81. [MEDLINE: 19323965]
8. Osuntokun O, Kane JM, Kryzhanovskaya LA, Xu W, Stauffer V, Watson SB. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. International Journal of Neuropsychopharmacology 2008;11(Suppl 1):153.
9. Watson SB, Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer V. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
10. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al.The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology 2006;187(3):312-20.
11. Beuzen JN, L'Italien G, Hanssens L, Marcus RN, McQuade RD, Carson WH. Changes in prolactin levels and arizona sexual experience scale (ASEX) scores among patients switched from risperidone to aripiprazole in the schizophrenia trial of aripiprazole (STAR) study. Schizophrenia Bulletin 2007;33(2):421-2.
12. Blonde L, Kan HJ, Gutterman EM, L'Italien GJ, Kim MS, Hanssens L, et al.Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care. Journal of Clinical Psychiatry 2008;69(5):741-8. [MEDLINE: 18435564]
13. Hanssens L, L'Italien G, Marcus RN, McQuade RD, Carson WH, Beuzen JN. Reasons for switching from previous therapy and preference of medication in the large, randomized, naturalistic schizophrenia trial of aripiprazole (STAR). Schizophrenia Bulletin 2007;33(2):432.
14. Hanssens L, L' Italien G, McQuade R, Iwamoto T, Pans M. Evaluation of quality of life in community-treated schizophrenic patients: a naturalistic, open-label study comparing aripiprazole to standard-of-care (Schizophrenia Trial of aripiprazole: STAR study). European Psychiatry 2006;21(Suppl 1):S99.
15. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al.A multi centre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenic Trial of aripiprazole: (STAR) study. Wiadomosci Psychiatryczne 2008;11(2):105-19.
16. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al.A multi centre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of aripiprazole: (STAR) study. European Psychiatry 2007;22(7):433-43. [MEDLINE: 17555947]
17. King D, Knapp M, Thomas P, Razzouk D, Loze JY, Kan HJ, et al.Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: Star study. Current Medical Research and Opinion 2011;27(2):365-74.
18. Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD. Changes in weight and weight-related quality of life in a multi centre, randomized trial of aripiprazole versus standard of care. European Psychiatry 2008;23(8):561-6. [MEDLINE: 18374544]
19. L'Italien G, Hanssens L, Kan HJ, Baker RA, Marcus RN, McQuade RD, et al.Metabolic effects of aripiprazole versus olanzapine, quetiapine, or risperidone (the STAR trial). Schizophrenia Bulletin 2007;33(2):439.
20. L'Italien GJ, Blonde L, Hanssens L, McQuade R. Prevalence of diabetes/cardiovascular risk factors among schizophrenia patients treated with atypical antipsychotics in a multicenter, randomized, naturalistic, open-label study (Schizophrenia Trial of aripiprazole: STAR study). Diabetes 2006;55(Suppl 1):A538.
21. Lltalien GJ, Hanssens L, Marcus RN, McQuade RD. Evidence of antipsychotic treatment selection based on metabolic risk factors among community-based schizophrenia patients (The STAR Trial). Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007.
22. Millet B. A multicenter, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients (Schizophrenia Trial of aripiprazole - STAR). http://www.clinicaltrials.gov 2005.
23. Taylor D, Hanssens L, Loze J-Y, Pans M, L'Italien G, Marcus RN. Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study. European Psychiatry 2008;23(5):336-43.
24. Eli Lilly, Company. Olanzapine versus aripiprazole in the treatment of acutely ill patients with schizophrenia. Eli Lilly and Company Clinical Trial Registry 2004.
25. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(6):601-7. [MEDLINE: 19011427]
26. Stauffer V, Kinon B, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
27. Abou Gharbia N, McQuade R, Jody D, Kujawa M, Carson W, Iwamoto T, et al.Comparative study of the long-term effects of aripiprazole and olanzapine treatment on body weight. Proceedings of the Thematic Conference of the World Psychiatric Association on "Treatments in Psychiatry: An Update" 2004 Nov 10-13; Florence, Italy. 2004.
28. Blonde L, Ray S, Corey-Lisle PK, Cislo PR, L'Italien G. The risk of new-onset type 2 diabetes and coronary heart disease in chronic schizophrenic patients treated with aripiprazole and olanzapine. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S275.
29. Jody D, McQuade RD, Kujawa M, Carson W, Iwamoto T, Archibald D, et al.Long-term weight effects of aripiprazole versus olanzapine. Schizophrenia Research 2004;67(1):187.
30. McQuade RD, Jody D, Kujawa MJ, Carson WH, Iwamoto T, Archibald DG, et al.Long-term weight effects of aripiprazole versus olanzapine. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003.
31. McQuade RD, Kujawa M, Saha AR, Ingenito GG, Ali MW, Luo X, et al.Aripiprazole for long-term maintenance treatment of schizophrenia. Schizophrenia Research 2003;60(1):295.
32. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al.A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Journal of Clinical Psychiatry 2004;65(Suppl 18):47-56. [MEDLINE: 15600384]
33. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al.A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. Journal of Clinical Psychiatry 2004;65(Suppl 18):47-56.
34. Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. Journal of Clinical Psychiatry 2009;70(3):318-25. [MEDLINE: 19192469]
35. Potkin SG, Kujawa M, Carson WH, Saha AR, Ali M, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research 2003;60:300.
36. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al.Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003;60(7):681-90.
37. Riera L, Hu R, Stock E, Nyilas M, Torbeyns A, Borian F, et al.Broad effectiveness trial with aripiprazole. Schizophrenia Research 2004;67(1):157.
38. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al.A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With aripiprazole (BETA). Schizophrenia Research 2006;84(1):77-89.
39. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189:259-66.
40. Sanchez R, Kostic D, Stock E, Torbeyns AF, Kerselaers W, Nyilas M, et al.Aripiprazole vs olanzapine in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week open-label extension study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
41. Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamato T, et al.Broad effectiveness trial with aripiprazole in Europe Eu-Beta. Proceedings of the 13th Congress of the Association of European Psychiatrists; 2005 Apr 2-6; Munich, Germany. 2005.
42. Beuzen J-N, Pans M, Modell S, Hagens P, McQuade R, Iwamoto T, et al.Naturalistic study of aripiprazole treatment. Proceedings of the XIII World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt. 2005.
43. Beuzen J-N, Schirr K, Pans M, Hagens P, Kostic D, Carson W, et al.Effectiveness of aripiprazole in a naturalistic setting: a European multicenter study. Proceedings of the 13th Biennial Winter Workshop on Schizophrenia Research; 2006 Feb 4-10; Davos, Switzerland. 2006.
44. Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al.A prospective, multi centre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with aripiprazole in Europe (EU-BETA). Current Medical Research and Opinion 2007;23(10):2313-23. [MEDLINE: 17706003]
45. Pfizer. A study comparing the efficacy and safety of ziprasidone and aripiprazole for the treatment of schizophrenia or schizoaffective disorder in hospitalized patients. http://www.clinicaltrials.gov 2008.
46. Zimbroff D, Warrington L, Loebel A, Yang R, Siu C. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, 4-week study. International Clinical Psychopharmacology 2007;22(6):363-70. [MEDLINE: 17917555]
47. Allen M, Talbott S, Eudicone J, McQuade R, Pikalov A. Similar rates of agitation, anxiety and insomnia in sedating and non-sedating antipsychotics: evaluating clinical trial results with aripiprazole, haloperidol and olanzapine. Schizophrenia Bulletin 2007;33(2):418.
48. Anon. Effectiveness of antipsychotic combination with psychosocial intervention on outcome of patients with schizophrenia. http://www.clinicaltrials.gov 2008.
49. Bergman M, Friedman JI, Stawarz K, Bowman A, Siever L, Cavagna M, et al.A double blind placebo controlled study of guanfacine adjunctive treatment to atypical antipsychotics for cognitive dysfunction in schizophrenia. http://www.clinicaltrials.gov 2007.
50. Bristol-Myers Squibb, Otsuka America Pharmaceutical. A multicenter, randomized, double-blind, placebo-controlled, 16 week study of aripiprazole used as dual therapy in the treatment of patients with chronic stable schizophrenia or schizoaffective disorder demonstrating an inadequate response to quetiapine or risperidone monotherapy. http://www.clinicaltrials.gov 2006.
51. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology 2000;10(Suppl 3):S309.
52. Casey D, L'Italien G, Waldeck R, Cislo P, Carson W. Metabolic syndrome comparison between olanzapine, aripiprazole, and placebo. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17- 22; San Francisco, California, USA. 2003.
53. Chen J-D, Zhao J-P, Li L-H, Guo X-F, Zhai J-G, Wang C-Y, et al.A multi centre, randomised and double-blind controlled trial of aripiprazole in treatment of schizophrenia. Chinese Journal of New Drugs and Clinical Remedies 2005;11:845-8.
54. Colombo GL, Caruggi M, Di Matteo S, Rossi A. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatric Disease and Treatment 2008;4(5):967-76.
55. Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, et al.Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophrenia Research 2002;53(3 Suppl 1):27.
56. Fawzi M, Fawzi M Jr. Aripiprazole, olanzapine and olanzapine-clomipramine combination in schizophrenia with obsessive-compulsive symptoms. World Psychiatry 2009;8(Suppl 1):NRS5.4.
57. Fleischhacker W, Heikkinen ME, Olie JP, Dewaele P, McQuade R, Hennicken D, et al.Long-term effect on weight of aripiprazole-clozapine in schizophrenia patients with suboptimal response on clozapine. European Neuropsychopharmacology 2008;18:S447.
58. Markovic O. A multicenter, comparative, randomized, double-blind, placebo controlled study on the effect on weight of adjunctive treatment with aripiprazole in patients with schizophrenia. http://www.clinicaltrials.gov 2006.
59. Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al.Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research 2009;113(1):49-55.
60. Henderson DC, Fan X, Copeland PM, Borba CP, Freudenreich O, Evins AE, et al.Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. Journal of Clinical Psychopharmacology 2009;29(2):165-9.
61. Roussel JJ, Machon DA, Henderson DC. A placebo-controlled, cross-over trial of aripiprazole added to obese olanzapine-treated patients with schizophrenia. http://www.clinicaltrials.gov 2006.
62. Janssen F. A comparative, randomized, open-label, multicenter study on the efficacy and safety of switch treatment with aripiprazole in schizophrenic out-patients who are experiencing insufficient efficacy with risperidone and/or safety and tolerability issues, while on risperidone. http://www.clinicaltrials.gov 2005.
63. Kim YS. A double-blind randomized placebo controlled study of aripiprazole augmentation for clozapine-treated patients with refractory schizophrenia. http://www.clinicaltrials.gov 2006.
64. Kim C-Y. A multi-center, randomized, open, treatment-switching study from orally administered antipsychotic monotherapy in the treatment of chronic schizophrenic and schizoaffective patients. http://www.clinicaltrials.gov 2006.
65. Kim CY, Chung S, Lee JN, Kwon JS, Kim DH, Kim CE, et al.A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 2009;24(4):181-8. [MEDLINE: 19451828]
66. Lan T, Chiu H, Hu T, Huang H, Wu B, Tuan Y. Prolactin level as an indicator to clinical psychopathological severity in aripiprazole treated schizophrenia. European Neuropsychopharmacology 2008;18:S440.
67. Liang S. A multi-center, randomized, double-blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia. http://www.clinicaltrials.gov 2005.
68. Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry 2011;44(3):109-13.
69. Ma Q, Lian H-T, Li L-X. A study of aripiprazole combined with clozapine in refractory schizophrenia. Medical Journal of Chinese People's Health 2007;19(12):1046, 1048.
70. Medori R, Wapenaar R, De Arce R, Rouillon F, Gaebel W, Cordes J, et al.Relapse prevention and effectiveness in schizophrenia of risperidone long-acting injectable (rlai) versus quetiapine or aripiprazole. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
71. Millar H, Felter C, Landsberg W. The effects of aripiprazole in combination with clozapine: patient functioning results from a double-blind, 16-week study in patients with schizophrenia (CN138-170). Journal of Psychopharmacology 2008;22(5):A17.
72. Mortimer AMP. Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia. Evidence-Based Mental Health 2004;7(2):41. [MEDLINE: 15107337]
73. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al.Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics 2009;19(1):91-4. [MEDLINE: 18849890]
74. Namey LB, Henderson DC. Aripiprazole for clozapine associated medical morbidity. http://www.clinicaltrials.gov 2006.
75. Newcomer JW, L'Italien G, Vester-Blokland, McQuade RD, Carson WH, Marcus RN. Improvement of non-hdl cholesterol levels among patients randomized to aripiprazole versus olanzapine. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada. 2006.
76. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, et al.Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 2008;106(2-3):300-7.
77. Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, et al.Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine. Schizophrenia Research 2008;106(2-3):300-7.
78. Pae CU, Serretti A, Chiesa A, Mandelli L, Lee C, Kim J, et al.Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study. European Neuropsychopharmacology 2009;19(8):562-70.
79. Ray S, Corey-Lisle PK, Cislo PR, L'Italien G, Weiden P. An economic evaluation of aripiprazole compared to olanzapine based on metabolic side-effect profile. Journal of the European College of Neuropsychopharmacology 2004;14(Suppl 3):S279.
80. Remington G. Refractory schizophrenia: Adding aripiprazole to clozapine reduces negative but not overall symptoms. Evidence-Based Mental Health 2009;12(2):51.
81. Schreiner A, De Arce R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, et al.Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Proceedings of the 9th World Congress of Biological Psychiatry; 2009 Jun 28-Jul 2; Paris, France. 2009.
82. Shim JC, Kelly DL, Jung DU, Seo YS, Kim YH, Conley RR. Adjunctive treatment with a dopamine partial agonist, aripiprazole for antipsychotic induced hyperprolactinemia. European Neuropsychopharmacology 2006;16(Suppl 4):S405.
83. Takeuchi H, Suzuki T, Uchida H, Nakajima S, Nomura K, Kikuchi T, et al.A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. Journal of Clinical Psychopharmacology 2008;28(5):540-3.
84. Talbott S, Buckley P, Eudicone J, McQuade R, Van-Tran Q. Akathisia in schizophrenia patients treated with aripiprazole, haloperidol, or olanzapine-analyses of the first 12 weeks of three double-blind, long-term trials. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1; Colorado Springs, Colorado, USA 2007.
85. Taylor D. Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia. Evidence-Based Mental Health 2007;10(3):76. [MEDLINE: 17652558]
86. Watts KL, Wilson H, Tang T. Estimating and reducing the cardiovascular risk of patients with schizophrenia drugs from lipid measures and ischemic electrocardiographic changes. http://www.clinicaltrials.gov 2006.
87. Yang S, Gao S, Wu X. A control study of aripiprazole vs. clozapine in the treatment of refractory schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(1):15-6.
88. Ai C-Q, Chen S-M. Comparison study in the treatment of schizophrenia between aripiprazole and clozapine. Linchuang Jingshen Yixue Zazhi 2008;18(1):53-4.
89. An C. Controlled study of clozapine and aripiprazole in the treatment of schizophrenia 2008;11(4):213-4.
90. Comparative study on the efficacy of aripiprazole and clozapine in treatment of schizophrenia 2007;1(4):39-40.
91. Ban N, Cui J-B. Analysis of the efficacy of aripiprazole and quetiapine in the treatment of schizophrenia. Occupation and Health 2008;24(3):292-3.
92. Bao L-Y, Wang K-M. The effectiveness of aripiprazole combined with clonazepam treated with agitation in schizophrenia. Medical Journal of Chinese People's Health 2007;19(3):198-200.
93. Chang S. A control study of aripiprazole vs. risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(4):335-6.
94. Chen H, Liu Z, Gong J, Chen H, Hu D, Wang D. Comparative study of therapeutic effects between aripiprazole and risperidone on schizophrenia. Shanghai Medical and Pharmaceutical Journal 2006;27(9):404-6.
95. Chen J, Zhou Y, Zha X-Y. A comparative study of aripiprazole and clozapine in the treatment of first-episode schizophrenia. Shandong Archives of Psychiatry 2007;20(2):97-8.
96. Chen Q-S, Li Y-H, Qu L-J. A comparative study of aripiprazole and risperidone in the treatment of the first episode schizophrenia. Medical Journal of Chinese People's Health 2008;20(5):394-5.
97. Comparative study between aripiprazole and olanzapine in the treatment of agitated schizophrenia. Linchuang Jingshen Yixue Zazhi 2009;19(4):261-2.
98. Dai J-P, Zhao Z-H, Liu G-X. Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia. Chinese Journal of Behavioral Medical Science 2005;14(8):712-4.
99. Dai T. A comparison of schizophrenia with aripiprazole and risperidone. Journal of the Datong Medical College 2006;26(1):14-5.
100. Du B, Zhao S-M, Tian G-Q. Study on effects of aripiprazole on serum prolactin level and body weight. Chinese General Practice 2006;9(13):1065-6.
101. Fan W-l, Yu C-M, Wen J-S. Efficacy analysis of aripiprazole and clozapine in the treatment of schizophrenia. Journal of North Sichuan Medical College 2005;20(4):377-9.
102. Feng Y, Yan X, Zhao Z. The clinical study on aripiprazole and risperidone in treatment of first-onset schizophrenia. Chinese Journal of Health Psychology 2006;14(4):418-9.
103. Guan H-Y, Wang K-Q, Jiang L, Geng H-S, Li Q-X, Liu Z-R, et al.A controlled study of efficacy between aripiprazole and risperidone in the treatment of patients. Linchuang Jingshen Yixue Zazhi 2007;17(4):241-3.
104. Guo X-F, Chen J-D, Zhao J-P. A randomized and double-blind controlled clinical trial of aripiprazole in the treatment of schizophrenia. Hunan Medical Journal 2006;23(5):716-8.
105. Han P, Zhang Y-H, Zhang Y-Q. A controlled study of schizophrenia treated with aripiprazole and clozapine. Clinical Journal of Rehabilitation in Theory and Practice 2005;11(10):853-4.
106. Han P, Zhang Y-H, Zhang C-Z. Quality of life in schizophrenics treated with aripiprazole or clozapine. Chinese Journal of Rehabilitation Theory and Practice 2006;12(11):995-6.
107. Han Y, Li Y, Ren C. Clinical effect of the domestic olanzapine and aripiprazole in the treatment of schizophrenia. Chinese Journal of Health Psychology 2007;15(1):28-9.
108. Huang X, Du W, Xue S, Tong Z, Jiang Z. Clinical efficacy of aripiprazole and risperidone in treating schizophrenia and their influence 2008;10(2):77-80.
109. Ji D-C, Yu C-X, Sun Y-J, Huang M, Huang Q. A study of aripiprazole and risperidone in treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi 2007;17(4):261-2.
110. Jiang Y-H, Shen Z-X. A comparison between the therapeutic effects of aripiprazole and risperidone in the treatment of schizophrenia. Herald of Medicine 2007;26(10):1147-8.
111. Kuang L-P, Xue Z-M. A controlled study on compliance of schizophrenia treated with aripiprazole and clozapine. Chinese Journal of Clinical Psychology 2006;14(4):426-7.
112. Kuang L-P. A controlled study on quality of life of schizophrenia treated with aripiprazole and clozapine. Medical Journal of Chinese Civil Administration 2006;18(9):690-1.
113. Li G-R, Lu P-X, Li Y-D. A comparative study of aripiprazole and risperidone in the treatment of first-episode schizophrenia. Shandong Archives of Psychiatry 2006;19(3):196-7.
114. Li L-X, Lian H-T. A comparative study of aripiprazole and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2006;18(9):723-4.
115. Li D, Yu L-B, Zha Z-Q. A comparative study on quality of life of female schizophrenics treated with aripiprazole. Medical Journal of Chinese People's Health 2007;19(5):170-2.
116. Li A-F, Yao J-X, Liao X-H. A controlled study of domestic aripiprazole and clozapine in the treatment of refractory schizophrenia. Medical Journal of Chinese People's Health 2007;19(5):165-7.
117. Li M, Wu N, Li Y-F. Comparative study of influence of aripiprazole on life quality in schizophrenic patients. Chinese Journal of Health Psychology 2007;15(10):956-7.
118. Li H. Comparison of efficacy and safety of aripiprazole and ziprasidone in the treatment of schizophrenia. International Medicine and Health Guidance News 2007;13(11):77-9.
119. Li C, Deng L, Feng W. Control studies of domestic aripiprazole vs. risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(2):100-2.
120. Li Q, Li G, Li G. Effects of aripiprazole and clozapine on life quality of schizophrenics. Journal of Clinical Psychosomatic Diseases 2007;13(5):404-6.
121. Lin C. A controlIed study of aripiprazole and risperidone in treatment of first-episode schizophrenia. Chinese Journal of Health Psychology 2006;14(6):660-1.
122. Liu W, Yang K, Zuo X. A control study on aripiprazole and risperidone in the treatment of schizophrenia. Chinese Journal of Health Psychology 2006;14(4):420-1.
123. Liu S, Ren C, Song X. Comparative study between aripiprazole and clozapine in the treatment of first-episode schizophrenia. Chinese Journal of Health Psychology 2006;14(6):658-9.
124. Liu G, Cai Y. A comparison study on the efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia. Modern Hospital 2007;7(8):36-7.
125. Liu B. A control study on aripiprazole vs. clozapine in the treatment of refractory schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(6):500-1, 507.
126. Liu L, Xinag H. Compared effect and safety analysis of aripiprazole in late-onset schizophrenia. Sichuan Mental Health 2007;20(3):142-4.
127. Liu W, Zhang X. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms. Chinese Journal of Health Psychology 2008;16(2):124-5.
128. Lou T, Li N, Wu X-Y, Wang C-S. Effect of aripiprazole on late-onset schizophrenia and cognitive function. Chinese New Drugs Journal 2007;16(20):1709-12.
129. Luo X, An B-F. Comparison of quetiapine and aripiprazole in the treatment of first episode schizophrenia. Linchuang Jingshen Yixue Zazhi 2008;18(3):191-2.
130. Lv X-M, Jia Z-L, Liu C-J. Effect of aripiprazole on body weight and blood glucose in the treatment of first-episode schizophrenia. Shandong Archives of Psychiatry 2006;19(3):181-2.
131. Lv T-H, Jin C-X. A comparative study on aripiprazole and risperidone in the treatment of schizophrenic patients. Medical Journal of Chinese People's Health 2007;19(5):181-2.
132. Mai G, Cai G-H, Huang J-M. Comparative study on the effect of aripiprazole and risperidone on schizophrenia. Chinese Journal of Rehabilitation 2005;20(3):184-5.
133. Pan G. A controlled study of aripiprazole and risperdal in the treatment of schizophrenia. Chinese Journal of Health Psychology 2007;15(4):363-4.
134. Peng X, Huang Y, Liu X-Y. A clinical analysis of aripiprazole and quetiapine in treatment of first episode schizophrenia. Linchuang Jingshen Yixue Zazhi 2007;17(5):329-30.
135. Peng Z-Y, Mao W-L. Comparative study between aripiprazole and clozapine in the treatment of schizophrenia. Journal of the Gannan Medical College 2007;27(2):237-8.
136. Pu S-B, Liang J-X, Zhang W-S. The comparison of blood prolactin and body index in the female patients with psychosis treated by aripiprazole and risperidone. Medical Journal of Chinese People's Health 2007;19(5):163-4, 7.
137. Shang H. A controlled study of aripiprazole vs. risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2008;14(2):119-20, 133.
138. Shen J-Q, Shi J-F. A controlled study on aripiprazole and risperidone in the treatment of schizophrenic patients. Chinese Journal of Modern Applied Pharmacy 2006;23(7):714-6.
139. Shuai H. Evaluating the effect and safety of aripirazole and risperidone. 2008;10(2):35-7.
140. Song Z-X, Xu L-P, Cai Z-K, Wang W-H, Wang G-J, Wang H-L. Clinical study of aripiprazole in treatment of hyperprolactinem ia caused by risperidone. Linchuang Jingshen Yixue Zazhi 2008;18(5):337-8.
141. Su Q, Huang H-R, Gao A-Q, Huang D. A comparative study of olanzapine and aripiprazole in treatment of schizophrenia. Linchuang Jingshen Yixue Zazhi 2008;18(6):409-10.
142. Sun F, Dong R, Wang Y. A randomized control study aripiprazole in the treatment of first-episode schizophrenia. Chinese Journal of Health Psychology 2006;14(6):642-3.
143. Sun Q, Guo H, Liu Y. Effect of aripiprazole on cognition function in patients with schizophrenic. Chinese Journal of Health Psychology 2006;14(4):424-6.
144. Tang Q, Lai G, Zhang J. Aripiprazole and risperidone in the treatment of female schizophrenics. Shanghai Archives of Psychiatry 2006;18(1):30-2.
145. Tang C-G, Wang R-C. Comparison of efficacy and safety of aripiprazole and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2007;19(17):727-8.
146. Tang Q. Aripiprazole and risperidone in the treatment efficacy of first-episode schizophrenia. Chinese Journal of Pharmaco Epidemiology 2010;19(1):13-5.
147. Tao S-W, Chen Q, Yang C, Pan R-D, Pan T-W, Li L, et al.A comparison of the effects on lipid metabolic among four different atypical antipsychotic agents. Journal of the Youjiang Medical College for Nationalities 2008;6:927-30.
148. Tong J, Yang Z. Control study of aripiprazole and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(1):7-10.
149. Wang R, Liu Y, Ning Z. A controlled study of aripiprazole vs clozapine in the treatment of first-episode schizophrenia. Journal of Clinical Psychosomatic 2005;11(4):301-2.
150. Wang H, Wang Y, Lu L. A comparative study between aripiprazole and risperidone in the treatment of chronic schizophrenia. Chinese Journal of Health Psychology 2006;14(6):650-1.
151. Wang D, Li Y, Feng Y. A controlled study of aripiprazole and risperidone in the treatment of schizophrenia. Journal of Clinical Psychosomatic Diseases 2006;12(4):245-6.
152. Wang X-Q, Zhou H-X, Zhang Y-L, Wang H-Y, Gao T-X, Xie P-L. Clinical study of aripiprazole and risperidone in treatment of schizophrenia. Journal of Clinical Psychiatry 2006;16(2):108-9.
153. Wang G-P, Xie R, Pei G-X, Zhang Y-L. Comparative study between aripiprazole and clozapine in the treatment of patients with schizophrenia. Journal of Clinical Psychiatry 2006;16(1):44-5.
154. Wang G-P. Effect of aripiprazole on quality of life of schizophrenic patients. Linchuang Jingshen Yixue Zazhi 2006;16(6):360-1.
155. Wang Y, Sun F, Zhang Z. Observation of therapeutic effect of aripiprazole in the treatment schizophrenic patients. Chinese Journal of Health Psychology 2006;14(4):427-8.
156. Wang D. Aripiprazole and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2007;19(17):751.
157. Wang K-Q, Guan H-Y, Jiang L, Geng H-S, Li Q-X, Liu Z-R, et al.A controlled study of effect on serum prolactin level between aripiprazole and risperidone. Linchuang Jingshen Yixue Zazhi 2007;17(3):154-6.
158. Wang L-Z, Weng J-Z, Zhuo Z-M. Comparative study on aripiprazole and risperidone in treatment of female schizophrenia 2007;19(1):42-3.
159. Wang Y, Chen T. Non-classical antipsychotic drugs for schizophrenia: cost - minimization analysis on 3 schemes. China Pharmacy 2007;18(32):2487-8.
160. Wang Y-C, Wang J-L, Yuan J-M. A controlled study of effect on schizophrenia serum prolactin level aripiprazole 2008;3(21):38-9.
161. Wei S-Z, Tang Q-S, Xu Z-N, Ruan X-J, Lu B. A randomized, double blind, double dummy parallel controlled study in the female first-episode schizophrenia treated with aripiprazole and quetiapine. Chinese Journal of Nervous and Mental Diseases 2006;32(6):511-7.
162. Wei S-Z. A randomized, double blind, double dummy parallel controlled study in the female first-onset schizophrenia treated with aripiprazole and quetiapine. Nervous Diseases and Mental Hygjene 2006;6(3):194-7.
163. Comparison of aripiprazole and risperidone in the treatment of female schizophrenia. Journal of the North Sichuan Medical College 2009;24(4):342-3.
164. Wu S, Liu H-Y, Huo X-P. A comparative study of aripiprazole and risperidone in the treatment of senile schizophrenia. Medical Journal of Chinese People's Health 2008;20(15):1723-4.
165. Xiao G-C, Wang D-P, Huang G-P. Comparative study on the clinical effect and the life quality of schizophrenic patients treated with aripiprazole and clozapine. 2007;1(2):28-9.
166. Xu M, Zheng G-X. Comparative study of aripiprazole and risperidone for schizophrenia. Jilin Medical Journal 2008;29(19):1629-30.
167. Aripiprazole and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2010;22(17):2180-4.
168. Yang L, Yang K, Yao X. A comparative between aripiprazole and clozapine in the treatment of schizophrenia. Sichuan Mental Health 2006;19(2):92-4.
169. Yang W, Liu X-Q, Li X-W. A randomized controlled clinical study of aripiprazole in the treatment of childhood schizophrenia. Hunan Medical Journal 2007;24(6):942-4.
170. Yang T-R, Song B-L, Yuan C-Q. Control study of aripiprazole and clozapine in treatment of patients with schizophrenia. 2007;19(2):234-5.
171. Yang J, Zhu G-H, Xie J. A comparative study of ziprasidone and aripiprazole in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2008;20(23):2760-1.
172. Yang X, Deng H, Wen W. Study of aripiprazole in treatment of first-episode schizophrenia. China Pharmaceuticals 2008;17(5):52-3.
173. Ye X-R, Xia X-l. A comparative study between aripiprazole and risperidone in treatment of first-onset schizophrenia. Wutaishan Hospital in Yangzhou City 2005;6:616-8.
174. Ye C-W, Pan D-J, Ni X-J, Pan J-L, Zhu G-D. Controlled study between aripiprazole and olanzapine on schizophrenia. Modern Research of Integrated Chinese and Western Medicine 2005;14(24):3199-200.
175. Yi F, Zhen L-L, Wang J-L, Xu L-F, Yang G-P. A comparative study of blood-glucose metabolism between aripiprazole and clozapine in treatment of patients with schizophrenia. Linchuang Jingshen Yixue Zazhi 2007;17(4):253.
176. Yu L. Effects of aripiprazole vs. clozapine on body weight and blood sugar levels of schizophrenics. Journal of Clinical Psychosomatic Diseases 2006;12(6):422-3.
177. Yu C-X, Ji D-C, Yuan H. The study of clinical efficacy of aripiprazole in the treatment for refractory schizophrenia. Shandong Jingshen Yixue 2006;19(4):263-5.
178. Yu L, Li B. A control study of aripiprazole and clozapine in the treatment of first-episode schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(2):115-6.
179. Yu L. Comparative study of aripiprazole and risperidone in the treatment of female schizophrenias. Chinese Journal of Health Psychology 2007;15(10):948-9.
180. Zeng D-Z, Chen K-Q, Hu Z-D. Influence of aripiprazole on life quality of the patients with schizophrenia. Chinese Journal of Rehabilitation 2006;21(4):288.
181. Zhang Y, Gao G, Zhang Q. A comparative study of aripiprazole versus olanzapine in the treatment of chronic schizophrenia. Chinese Journal of Health Psychology 2006;14(4):429-30.
182. Zhang Y, Li G, An B. Aripiprazole and risperidone in the treatment of schizophrenia. Chinese Journal of Health Psychology 2006;14(6):635-6.
183. Zhang X-L, Cui Y-Z, Yang X-S. Controlled study on aripiprazole in the treatment of schizophrenic patients who has response to clozapine. Medical Journal of Chinese Civil Administration 2006;18(9):753-4.
184. Zhang R-X, Cai Y-F, Zhao L-G. A comparative study of EKG changed by aripiprazole and clozapine in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2007;19(12):1016, 1018.
185. Zhang Y, Zhang H, Gu W. A control study of aripiprazole in the treatment of childhood schizophrenia. Journal of Clinical Psychosomatic Diseases 2007;13(2):122-4.
186. Zhang Z-L, Xiao X-Y, Nie B. Clinical control study of aripiprazole and risperidone in the treatment of first- episode schizophrenia. Modern Medicine and Health 2007;23(4):494-5.
187. Zhang J. Comparative investigation on aripiprazole and risperidone in the treatment of schizophrenia. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao] 2008;29(13):1542-3.
188. Aripiprazole and quetiapine in the treatment control study of first-episode schizophrenia. Chinese Journal of Health Psychology 2009;17(11):1299-300.
189. Aripiprazole and risperidone in the treatment of schizophrenia comparative analysis of 100 cases. Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease 2010;18(6):762.
190. Aripiprazole and clozapine in treatment refractory schizophrenia. West China Medical Journal 2010;25(6):1033-5.
191. Zhao L, Wang M, Wang B. A controlled study of aripiprazole versus quetiapine in the treatment of first-episode schizophrenia. Chinese Journal of Health Psychology 2006;14(6):663-4.
192. Zhao S-M, Du B, Li K-Q. A comparative study of aripiprazole versus risperdal in patients with schizophrenia. Medical Journal of Chinese People's Health 2007;19(5):195-7.
193. A control study on effect of domestic aripiprazole and clozapine in treatment of schizophrenia. Occupation and Health 2009;25(6):666-8.
194. Domestic aripiprazole and clozapine in the treatment of schizophrenia and safety control study. Occupation and Health 2009;25(6):666-8.
195. Zhe J, Shi X-Y, Tan T-C, Liu W-X, Tao P-Y, Wang J, et al.Comparative study of aripiprazole and risperidone in treatment of late onset schizophrenia. Linchuang Jingshen Yixue Zazhi 2007;17(5):327-8.
196. Zhi S-L. Comparison study of aripiprazole and risperidone on schizophrenia. Modern Journal of Integrated Traditional Chinese and Western Medicine 2005;14(21):2787-8.
197. Zhu P-J, Cheng Z-E, Zhang J, Zhu P-L, Zhan X-M. Clinical study of therapeutic effects of aripiprazole in treatment of patients with schizophrenia. China 2005;10:1194-6.
198. Zhu P-L, Zhu P-J, Chen Z-E, Zhang J, Zhan X-M, Li Q-Z. Treatment of 40 cases of schizophrenia with aripiprazole. Herald of Medicine 2006;25(6):536-8.
199. Zou K-Q, Jiang Q-L, Wang D. Comparative study on effects of aripiprazole and clozapine 2006;3(1):17-9.
200. Aripiprazole and risperidone in the treatment of schizophrenia 2007;45(17):87.
201. Aripiprazole and risperidone in the treatment of schizophrenia Medical Journal of Chinese People's Health 2008;20(19):2267, 2269.
202. Controlled clinical studies of aripiprazole and clozapine in the treatment of schizophrenia Medical Journal of Chinese People's Health 2007;19(12):1066-7.
203. Aripiprazole and clozapine in the treatment of chronic schizophrenia [Google Translate] Medical Journal of Liaoning 2009;23(4):211-2.
204. Comparison of the efficacy of aripiprazole and risperidone in the treatment of schizophrenia Sichuan Mental Health 2009;30(8):905-8.
205. Aripiprazole and clozapine treatment episode schizophrenia 2008;3(4):55-7.
206. Aripiprazole psychiatric symptoms and quality of life of patients with schizophrenia 2008;5(19):110-1.
207. Aripiprazole and risperidone in the treatment of refractory schizophrenia Medical Journal of Chinese People's Health 2008;20(3):224-5.
208. Clozapine, risperidone and aripiprazole adverse drug reactions cost - effectiveness analysis. Chinese Journal of Health Psychology 2010;18(6):646-8.
209. Aripiprazole and olanzapine schizophrenia Shandong Archives of Psychiatry 2009;22(5):339-40.
210. Aripiprazole and risperidone in the treatment episode schizophrenia Chinese Medical Journal of Metallurgical Industry 2008;25(3):276-7.
211. Aripiprazole and risperidone in the treatment of schizophrenia Journal of Medical Theory and Practice 2009;22(9):1072-3.
212. Aripiprazole and risperidone in the treatment of schizophrenia Journal of Medical Theory and Practice 2009;22(9):1072-3.
213. Aripiprazole and quetiapine in the treatment of schizophrenia [Google Translate] Shandong Archives of Psychiatry 2009;22(1):42-3.
214. Clinical comparison of aripiprazole and risperidone in the treatment of female schizophrenia Sichuan Mental Health 2009;22(2):115-6.
215. Aripiprazole and risperidone in the treatment of schizophrenia Medical Journal of Chinese People's Health 2008;20(23):2804.
216. Aripiprazole and risperidone in the treatment of schizophrenia control observation Journal of the Youjiang Medical College for Nationalities 2007;29(3):384-5.
217. Aripiprazole and risperidone in the treatment of schizophrenia 2008;21(2):139-40.
218. Aripiprazole and clozapine treatment of schizophrenia Linchuang Jingshen Yixue Zazhi 2007;17(2):126-7.
219. Aripiprazole impact on the quality of life in patients with schizophrenia Medical Journal of Chinese People's Health 2007;19(5):354, 356.
220. Control study on aripiprazole in the treatment of first-episode schizophrenia Chinese Journal of Health Psychology 2009;17(7):774-6.
221. Quetiapine and aripiprazole in the treatment of schizophrenia Chinese Journal of Health Psychology 2009;12:1416-7.
222. Quetiapine, aripiprazole treatment efficacy in patients with acute schizophrenia Shandong Archives of Psychiatry 2009;22(5):381-2.
223. Comparative analysis of aripiprazole and risperidone in the treatment of female schizophrenia Sichuan Mental Health 2008;21(1):34-5.
224. Olanzapine and aripiprazole in the treatment of schizophrenia Medical Journal of Chinese People's Health 2010;22(8):970-86.
225. Aripiprazole comparative study of risperidone in the treatment of schizophrenia Journal of Medical Forum 2009;30(19):67.
226. Compare the aripiprazole with risperidone to treat schizophrenia disease Journal of the Mudanjiang Medical College 2008;29(3):20-2.
227. Aripiprazole and risperidone on glucose and lipid Linchuang Jingshen Yixue Zazhi 2009;19(5):343-5.
228. Aripiprazole and clozapine in the treatment of refractory schizophrenia Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao] 2008;29(14):1703-4.
229. Aripiprazole and risperidone in the treatment of schizophrenia Fujian Medical Journal 2007;29(6):117-8.
230. Controlled clinical observation of aripiprazole and risperidone in the treatment of schizophrenia Guangzhou Medical Journal 2008;39(3):52-3.
231. Aripiprazole and risperidone in the treatment of schizophrenia Journal of Baotou Medical College 2009;25(6):41-2.
232. Comparison of the efficacy of aripiprazole and risperidone in the treatment of schizophrenia Medical Journal of Chinese People's Health 2008;20(20):2386, 2435.
233. Aripiprazole and clozapine in treatment refractory schizophrenia comparative observation People's Military Surgeon 2009;52(12):822-3.
234. Aripiprazole and risperidone in the treatment of schizophrenia randomized double-blind controlled study Linchuang Jingshen Yixue Zazhi 2010;20(1):35-7.
235. Aripiprazole and clozapine treatment of schizophrenia analysis Journal of Clinical Psychosomatic Diseases 2007;13(6):548-9.
236. Aripiprazole and clozapine in the treatment of chronic schizophrenia Medical Journal of Chinese People's Health 2010;22(17):2180-4.
237. Aripiprazole and risperidone in the treatment of schizophrenia compared efficacy 2010;19(4):52-3.
238. Aripiprazole and risperidone in the treatment of female controlled study of schizophrenia Guangdong Medical Journal 2009;30(6):987-8.
239. Aripiprazole and risperidone in patients with first-episode schizophrenia comparative efficacy and safety study 2010;17(22):37-9.
240. The comparison for effect of treating schizophrenia with aripiprazole and risperidone Chinese Journal of Ethnomedicine and Ethnopharmacy 2009;6:33.
241. Aripiprazole and quetiapine controlled study for the treatment of schizophrenia Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine 2008;8(1):9-10.
242. Risperidone and olanzapine and aripiprazole on cognitive function in chronic schizophrenia 2010;4(9):1709-12.
243. Aripiprazole and risperidone in the treatment of schizophrenia compared [Google Translate]. Baotou Medical Journal 2009;33(1):13-4.
244. Aripiprazole and risperidone in the treatment of schizophrenia 2009;4(18):166-7.
245. Aripiprazole and clozapine treatment of schizophrenia control study of efficacy and safety 2009;25(16):135-41.
246. Aripiprazole and risperidone in the treatment of schizophrenia Medical Journal of Chinese People's Health 2007;19(12):1064, 1067.
247. Aripiprazole and quetiapine in the treatment of schizophrenia 2007;30(11A):49-50.
248. Aripiprazole and clozapine in the treatment of schizophrenia Acta Medicinae Sinica 2010;23(4):391-3.
249. Aripiprazole and olanzapine on body weight, blood glucose control study effects Linchuang Jingshen Yixue Zazhi 2009;19(5):339-40.
250. Aripiprazole in the treatment of female schizophrenia 2008;46(13):100-1.
251. Control study of aripiprazole and clozapine in the treatment of the negative symptoms of schizophrenia Sichuan Mental Health 2009;22(1):38-9.
252. Aripiprazole and clozapine in the treatment of negative symptoms of schizophrenia Sichuan Mental Health 2009;22(1):38-9.
253. Aripiprazole and risperidone in the treatment of schizophrenia Shandong Archives of Psychiatry 2007;20(5):313-4.
254. Compliance control study of aripiprazole and risperidone in the treatment of patients with schizophrenia. Guangxi Medical Journal 2008;30(1):30-1.
255. Olanzapine and aripiprazole in the treatment of refractory schizophrenia control study of 70 cases Medical Journal of Chinese People's Health 2010;22(11):1365-6.
256. Aripiprazole and risperidone in the treatment of schizophrenia Medical Information 2010;3:641-3.
257. Aripiprazole (Booz Qing) and risperidone in the treatment of schizophrenia in the clinical control study Jiangxi Medical Journal 2009;44(8):799-800.
258. Aripiprazole in the treatment of schizophrenia clinical observation;. Journal of the Changzhi Medical College 2007;21(2):110-1.
259. Ziprasidone treatment of schizophrenia with predominantly negative symptoms Linchuang Jingshen Yixue Zazhi 2008;18(3):206-7.
260. Aripiprazole and risperidone in the treatment of schizophrenia 2007;4(11):44.
261. New antipsychotic drug aripiprazole on glucose metabolism and glycosylated hemoglobin Hebei Medical Journal 2009;31(14):1752-3.
262. Ziprasidone and aripiprazole in the treatment of schizophrenia 2009;41(3):199-200.
263. Aripiprazole and risperidone in the treatment of chronic schizophrenia. Medical Journal of Chinese People's Health 2008;20(4):284, 300.
264. Ziprasidone and aripiprazole in the treatment of schizophrenia with predominantly negative symptoms Journal of the Xianning Medical College 2009;23(2):106-8.
265. Domestic aripiprazole and risperidone in the treatment of female schizophrenia Medical Journal of Chinese People's Health 2008;20(23):2781, 2783.
266. Aripiprazole and risperidone in the treatment of schizophrenia efficacy analysis 2009;15(170):101-2.
267. Comparative study of the effects of ariplprazole and risoeridone on the therapeutic effect and patients' weight in patients with schizophrenia Hebei Medical Journal 2009;31(4):407-9.
268. Aripiprazole and risperidone in the treatment of schizophrenia Tianjin Pharmacy 2010;22(1):41-3.
269. Aripiprazole and risperidone in the treatment of schizophrenia 2010;22(6):1051-2.
270. Aripiprazole and quetiapine in the treatment of women with schizophrenia. Chinese General Practice 2010;13(5):46-7.
271. Aripiprazole and clozapine in treatment refractory schizophrenia randomized controlled study. Chongqing Medical Journal 2009;38(1):87-8.
272. Quetiapine and aripiprazole in the treatment control study of first-episode schizophrenia 2009;2(3):71.
273. Aripiprazole and risperidone in the treatment of male schizophrenia efficacy and sexual function Hunan Medical Journal 2008;25(6):1111-3.
274. Aripiprazole and risperidone in the treatment of schizophrenia 2010;11(2):190-2.
275. Aripiprazole and risperidone on serum prolactin levels. Medical Journal of Liaoning 2009;23(4):221-2.
276. Aripiprazole and risperidone in the treatment of schizophrenia 2008;46(14):91-2.
277. Effects were compared aripiprazole in the treatment of elderly schizophrenia. Sichuan Mental Health 2008;21(1):28-9.
278. Control study of domestic aripiprazole and risperidone in the treatment of schizophrenia Journal of the Youjiang Medical College for Nationalities 2008;5:755-6.
279. Aripiprazole in the treatment of schizophrenia, efficacy and safety analysis. Modern Practical Medicine 2008;20(6):457-8.
280. Aripiprazole and olanzapine treatment of female control study of patients with schizophrenia. 2009;1(19):28-9.
281. Aripiprazole and risperidone in the treatment of children with schizophrenia. 2008;27(6):465-6.
282. Aripiprazole and clozapine treatment of refractory schizophrenia. Chinese Journal of Misdiagnostics 2008;8(18):4304-5.
283. Aripiprazole impact on the quality of life of patients with schizophrenia 2007;5(11c):15-6.
284. Aripiprazole and risperidone in the treatment of schizophrenia. Medical Journal of Chinese People's Health 2010;22(17):2249-50.
285. Aripiprazole and risperidone in the treatment of schizophrenia in the clinical control study. Medical Journal of Chinese People's Health 2010;22(17):2243-4.
286. Aripiprazole and risperidone in the treatment of female schizophrenia. Shanxi Clinical Medicine 2010;19(9B):1232-4.
287. Aripiprazole and clozapine on quality of life of patients with schizophrenia. Medical Journal of Chinese People's Health 2010;22(15):1939-41.
288. Aripiprazole and quetiapine in the treatment of schizophrenia. Shandong Archives of Psychiatry 2009;22(1):53-4.
289. Aripiprazole and risperidone in the treatment of schizophrenia 2010;16(4):140-1.
290. Aripiprazole and risperidone in the treatment of female schizophrenia. Modern Research of Integrated Chinese and Western Medicine 2008;17(35):5454-5.
291. Aripiprazole, quetiapine treatment of female episode schizophrenia.Shandong Archives of Psychiatry 2007;20(6):381-3.
292. A controlled study on compliance of schizophrenia treated with aripiprazole and risperidone. Proceedings of the 8th National Academic Congress of CSP with the Regional Meeting of the WPA; 2007 Sep 20-23; Shanghai. 2007.
293. Comparative Analysis of aripiprazole and risperidone in the treatment of schizophrenia negative emotions. Sichuan Mental Health 2009;22(1):39-40.
294. Aripiprazole and risperidone in the treatment of schizophrenia comparative analysis of negative emotion. Sichuan Mental Health 2009;22(1):39-40.
295. Second generation of psychiatric drugs 3 cost of the treatment of schizophrenia. Journal of Qiqihar Medical College [Qiqihar Yixueyuan xuebao] 2010;31(9):1379-80.
296. Aripiprazole and quetiapine in the treatment of schizophrenia control study of women. Medical Journal of Chinese People's Health 2010;22(5):511-6.
297. Aripiprazole and risperidone in the treatment of clinical studies of schizophrenia. Journal of Practical Medical Techniques 2007;14(31):4298-9.
298. Aripiprazole and clozapine treatment of schizophrenia with predominantly negative symptoms. Sichuan Mental Health 2008;21(2):107-9.
299. Efficacy of aripiprazole and risperidone in the treatment of early schizophrenia. Chinese Journal of Health Psychology 2009;17(6):643-4.
300. Comparative study on aripiprazole and risperidone in the treatment of female patients with schizophrenics 2009;12(2):77-9.
301. Olanzapine and aripiprazole treatment of schizophrenia 2009;4(16):166-7.
302. Control study of aripiprazole and clozapine in schizophrenia affect the quality of life in patients. Sichuan Mental Health 2007;20(2):80-2.
303. Aripiprazole and olanzapine in negative symptoms in schizophrenia. China Pharmaceuticals 2009;18(23):59-60.
304. Aripiprazole impact on the quality of life of the first female schizophrenic patients. Chinese Journal of Health Psychology 2009;24(142):54-5.
305. A comparative study in earlier schizophrenic patients treated with aripiprazole and risperidone 2009;7(16):15-7.
306. Bristol-Myers Squibb. Metabolic abnormalities - OPT. http://www.clinicaltrials.gov 2009.
307. Eli Lilly, Company. Study of olanzapine vs aripiprazole in the treatment of schizophrenia. Eli Lilly and Company Clinical Trial Registry 2003.
308. Essock SM, Covell NH, Carbuto M, Bielen K, Jabbour B, Saltz BL, et al.Effectiveness of switching antipsychotic medications. http://www.clinicaltrials.gov 2002.
309. Glorioso DK, Jeste DV. Metabolic effects of newer antipsychotics in older patients. http://www.clinicaltrials.gov 2005.
310. Hanssens L. A 16-Week, multicenter, randomized, open-label study to assess the effects of aripiprazole versus other atypical antipsychotics in the treatment of schizophrenic patients with metabolic syndrome. http://www.clinicaltrials.gov 2007.
311. Johnson & Johnson Pharmaceutical Research & Development LLC. A 2-year, prospective, blinded-rater, open-label, active-controlled, multicenter, randomized study of long-term efficacy and effectiveness comparing risperdal® consta® and abilify® (aripiprazole) in adults with schizophrenia. http://www.clinicaltrials.gov 2006.
312. Lehrer DS, Jewell M. Best event schizophrenia trial--a randomized double-blind trial of aripiprazole and risperidone in schizophrenia. http://www.clinicaltrials.gov 2008.
313. Lin C-C. Identification and treatment response prediction of antipsychotic-related metabolic syndrome. http://www.clinicaltrials.gov 2009.
314. Livingston M, Stroup TS, McEvoy JP, Rojas I, Gamel N, Glick I, et al.Clinical management of metabolic problems in patients with schizophrenia. http://www.clinicaltrials.gov 2007.
315. McCormack J, Robinson D, Tobias K, Petrides G, Robinson D, Sevy S, et al.Preventing morbidity in first episode schizophrenia, part II. http://www.clinicaltrials.gov 2006.
316. McEvoy JP. Metabolic signatures and biomarkers for aripiprazole. http://www.clinicaltrials.gov 2007.
317. Montoya D, Blizard R, Buckley PF, Holman T, Kerr J, Miller DD, et al.Preventing relapse: oral antipsychotics compared to injectables: evaluating efficacy (PROACTIVE). http://www.clinicaltrials.gov 2006.
318. Schweiger J, Flavin K, Rosen B, Spies A, Newcomer JW, Haupt D. Changes in adiposity and metabolic measures during medication switches to aripiprazole from other atypical antipsychotics. http://www.clinicaltrials.gov 2005.
319. Stroup TS, McEvoy JP, Swartz MS, Hamer RM, Perkins DO, Lieberman JA. Comparison of antipsychotics for metabolic problems (CAMP): a NIMH schizophrenia trials network study. Clinical Schizophrenia and Related Psychoses 2007;1(1):69-72.
320. Swartz M, Stroup TS, McEvoy JP, Rojas IA. Comparison of optimal antipsychotic treatments for adults with schizophrenia. http://www.clinicaltrials.gov 2008.
321. Vontur MG, Lopez J, Woolsey MD, Maples NL, Velligan DI. Do patients taking aripiprazole learn more in vocational skills training than patients taking olanzapine?. http://www.clinicaltrials.gov 2005.
322. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
323. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. American Journal of Psychiatry. 2nd Edition. American Psychiatric Publishing, Inc, 2004:1-114.
324. Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63-101.
325. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
326. Belgamwar Ravindra B, El-Sayeh Hany George G. Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD006622.pub2]
327. Bhattacharjee J, El-Sayeh Hany George G. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD006617.pub3]
328. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
329. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, et al.The problem of therapeutic efficacy indices.3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
330. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
331. Chaichan W. Evaluation of the use of the positive and negative syndrome scale-excited component as a criterion for administration of p. r. n. medication. Journal of Psychiatric Practice 2008;14(2):105-13. [PUBMED: 18360196]
332. Chakrabarti A, Adams CE, Rathbone J, Wright J, Xia J, Wong W, et al.Schizophrenia trials in China: a survey. Acta Psychiatrica Scandinavica 2007;116(1):6-9. [PUBMED: 17559595]
333. Cipriani A, Boso M, Barbui C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2]
334. Clarke M. Can you believe what you read in the papers?. Trials 2009; Vol. 10:55. [PUBMED: 19607671]
335. Deeks J. Issues in the selection for meta-analyses of binary data. Proceeding of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa. Cape Town: Cochrane Collaboration, 2000.
336. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
337. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
338. Duggan L, Dardennes R, El-Dosoky A, Fenton M, Indran S, Rathbone J. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2]
339. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
340. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3]
341. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
342. U. S. Federal Drug Administration CDER. Abilify (aripiprazole) tablets, medical review. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002 (accessed 18 August 2006).
343. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
344. Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf 2006.
345. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
346. Guy U. ECDEU assessment manual for psychopharmacology. National Institute of Mental Health, 1976.
347. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The quality of life scale: An instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 1984;10(3):388-98. [PUBMED: 6474101]
348. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185-94.
349. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
350. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org 2011.
351. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
352. Jelsma J, Mhundwa K, De Weerdt W, De Cock P, Chimera J, Chivaura V. The reliability of the Shona version of the EQ-5D. Central African Journal of Medicine 2001;47(1):8-13. [PUBMED: 11961858]
353. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al.Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry 2006;63:1079-6.
354. Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789-96.
355. Kane JM. Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585-93.
356. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
357. Kolotkin RL, Crosby RD. Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample. Quality of Life Research 2002;11(2):157-71. [PUBMED: 12018739]
358. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
359. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
360. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
361. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al.A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009;166(2):152-63. [DOI: 10.1176/appi.ajp.2008.08030368]
362. Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209-23.
363. Maayan N, Soares-Weiser K, Xia J, Adams CE. Antipsychotic combinations for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD009005]
364. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249-52.
365. Marvaha S, Johnson S. Schizophrenia and employment - a review. Social Psychiatry and Psychiatric Epidemiology 2004;39:337-49.
366. McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al.The Arizona Sexual Experience Scale (ASEX): reliability and validity. Journal of Sex & Marital Therapy 2000;26(1):25-40. [PUBMED: 10693114]
367. Moher D, Schulz KF, Altman D. The CONSORT Statement: revised recommendations for improving the quality of reports of parallel- group randomized trials. JAMA 2001;285:1987-1.
368. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD006629.pub2;: CD006629]
369. Möller HJ. New assessment of atypical antipsychotics [Aktuelle bewertung neuer/atypischer neuroleptika]. Nervenarzt 2000;71:329-44.
370. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
371. Pagadala B, Jayaram Mahesh B, Mitra L. Aripiprazole for psychosis-induced aggression or agitation. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008074]
372. Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD000088.pub3; PUBMED: 21154340]
373. Rivas-Vasquez RA. Aripiprazole: A novel antipsychotic with dopamine stabilising properties. Professional Psychology 2003;34(1):108-11.
374. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
375. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
376. Simpson EN, Angus JWF. A rating scale for extrapyramidal adverse effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
377. Tandon R, Devellis RF, Han J, Li H, Frangou S, Dursun S, et al.Validation of the investigator's assessment questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Research 2005;136(2-3):211-21. [PUBMED: 16115690]
378. Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia, "just the facts"What we know in 2008.2. Epidemiology and etiology. Schizophrenia Research 2008;102:1-18.
379. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al.A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. Journal of Clinical Epidemiology 2009;62(5):464-75. [PUBMED: 19348971]
380. Tsuang MT. Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Archives of General Psychiatry 1978;35:153-5.
381. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92.
382. Whitehead C, Moss S, Cardno A, Lewis G. Antidepressants for people with both schizophrenia and depression. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD002305; PUBMED: 12076447]
383. WHO. The World Health Report 2001 - Mental Health: New Understanding, New Hope. Geneva: World Health Organization, 2001.
384. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.The Leeds Outcomes Stakeholders Survey (LOSS) study. Proceedings of the 15th Cochrane Colloquium, Sao Paulo, 23-27 October 2007. 2007.
385. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
386. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, et al.Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD006569.pub3; PUBMED: 19821375]